Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 1231

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 9A
Chunk 1231
---
	Depreciation and amortization

			119,273

			186,049

			Share-based compensation

			729,642

			537,492

			Gain on loan forgiveness

			-

			(14,766
			)

			Changes in working capital items:

			Accounts and other receivable

			(377,987
			)

			356,339

			Prepaid expenses and other current assets

			107,832

			197,136

			Accounts payable and accrued liabilities

			(715,499
			)

			17,590

			Net cash used in operating activities

			(7,322,262
			)

			(4,890,205
			)

			Cash flows from financing activities:

			Proceeds from issuance of common shares and warrants

			7,717,634

			729,387

			Proceeds from issuance of Series A-1 preferred shares and warrants

			1,540,820

			-

			Proceeds from issuance of Series B-1 preferred shares

			8,340,000

			-

			Payments for issuance costs of common shares and warrants

			(328,953
			)

			(107,824
			)

			Payment for issuance costs of preferred shares

			(215,157
			)

			-

			Payment for issuance costs of warrants

			(23,446
			)

			-

			Repayment of debt

			-

			(29,532
			)

			Net cash provided by financing activities

			17,030,898

			592,031

			Effect of exchange rate changes on cash and cash equivalents

			46,216

			(25,903
			)

			Net change in cash and cash equivalents

			9,754,852

			(4,324,077
			)

			Cash and cash equivalents, beginning of year

			1,037,320

			5,361,397

			Cash and cash equivalents, end of year

			$
			10,792,172

			$
			1,037,320

The accompanying notes are an integral part of these consolidated financial statements.

F-6